Serene Sleep Palatal Implant System Clinical Confirmatory Trial in Participants Who Snore or Are Diagnosed With Mild-to-moderate Obstructive Sleep Apnea (OSA).
A Prospective, Non-Randomized, Multi-Center, Two-Arm Study Evaluating the Serene Sleep Palatal Implant System
This clinical investigation is a prospective, non-randomized, parallel-group clinical investigation conducted at two (2) investigative sites. Study participants will be assigned to one of two study groups, snoring and obstructive sleep apnea, in a parallel manner based on predefined eligibility criteria.
The study aims to evaluate and compare outcomes between the two groups under investigation. The primary endpoint for this study is to evaluate the adverse event profile of the Serene Sleep Palatal Implants, in comparison to those observed with the previously marketed Pillar Palatal Implants, in subjects treated for snoring and/or mild-to-moderate OSA.
The design allows for the concurrent enrollment and follow-up of participants in both arms, enabling direct observation of differences in safety across the groups over time.
研究概览
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Chief Technology Officer
- 电话号码:415-707-1107
- 邮箱:kelsey@serenesleep.com
学习地点
-
-
California
-
San Francisco、California、美国、94102
- Aesthetic Surgery Center
-
接触:
- Michael R Macdonald, MD
- 电话号码:415-956-3223
- 邮箱:Contactus@drMMacdonald.com
-
首席研究员:
- Michael R Macdonald, MD
-
-
Georgia
-
Evans、Georgia、美国、30907
- Augusta ENT
-
接触:
- Jonathan P Lindman, MD
- 电话号码:706-868-5676
- 邮箱:lindmanresearch@gmail.com
-
首席研究员:
- Jonathan P Lindman, MD
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
INCLUSION CRITERIA
A potential participant must meet ALL the following criteria to be enrolled into this study:
- Participant is ≥18 years of age.
- Participant has Body Mass Index (BMI) less than or equal to 30 kg/m²
- Participant has a tonsil grade less than or equal to 2
- Participant has a Friedman Tongue Position (FTP) I or II
- Participant is able to provide voluntary written informed consent.
For a snoring participant to be selected for the study:
Confirmed identification of palatal snoring
- Investigators will utilize standard of care clinical assessment methods to confirm the presence of palatal snoring prior to enrollment. These methods may include patient-reported history, physical examination of the upper airway, and auscultation or audio recordings.
Confirmed elimination of potential sleep apnea diagnosis
- If the evaluating doctor suspects that the participant may be experiencing OSA, investigators will utilize standard of care clinical assessment methods to confirm OSA.
- A resulting AHI <5 would classify the participant as an eligible snoring subject
For an OSA participant to be selected for study:
Confirmed identification of apnea caused by palatal collapse
- Investigators should be able to make this identification through intraoral evaluation in accordance with their standard of care
Confirmed mild-to-moderate classification of OSA
- If the evaluating investigator knows or suspects that the participant may be experiencing OSA, standard of care diagnostic methods will be used as confirmation.
- A resulting AHI between 5 and 30 would classify the participant as an eligible OSA subject.
EXCLUSION CRITERIA
A potential participant will be excluded from enrollment if ANY of the following conditions apply:
- A record of allergic reaction to polyethylene terephthalate (PET) / polyester
- An overly sensitive gag reflex
- Septal deviation or nasal obstruction
- Nasal polyps
- Severe seasonal allergies
- Soft palate length insufficient to accommodate implants
- Prior Diagnosis of Lingual tonsil hypertrophy
- Hypopharyngeal obstruction
- Previous pharyngeal surgery
- Previous upper respiratory tract cancer or radiation therapy
- Active respiratory tract infection
- Dysphagia or speech disorder
- Neurologic disorder
- Unstable psychiatric disorder
- Pregnant or breastfeeding
- History of falling asleep driving or Motor Vehicle Accident (MVA) due to sleepiness
- Clinical Presentation that suggests Severe OSAHS (ESS >20, participant report of choking or gasping during sleep, etc.)
- Marfan's Syndrome, Ehler-Danlos syndromes or other disorders of connective tissue and/or muscular tissue
- Other sleep disorders
- Other significant craniofacial anomaly
Participant is participating in any of the following:
- A study with the same or similar primary endpoint
- Any study in which the investigator determines may interfere with the results of this study
- Participant is unwilling to complete all study related assessments and follow-up visits
- Participant is unwilling or unable to abstain from all alcohol consumption for 24 hours leading up to the intake sleep study
- Participant is unwilling or unable to abstain from all smoking, vaping, and/or oral tobacco products for 48 hours following the procedure
- Participant has any other medical condition which in the opinion of the Investigator will make participation medically unsafe or interfere with the study results
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Snoring Group
Implant with the Serene Sleep Palatal Implant System
|
Serene Sleep Palatal Implant System
|
|
实验性的:Mild to Moderate OSA Group
Implant with the Serene Sleep Palatal Implant System
|
Serene Sleep Palatal Implant System
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Proportion of Participants with Implant Extrusion at 30 Days and Absence of Serious Adverse Device Effects (SADEs) [Hybrid Composite Safety Endpoint]
大体时间:From baseline to 30 days post-procedure
|
The primary endpoint for this study is to evaluate the adverse event profile of the Serene Sleep Palatal Implants, in comparison to those observed with the previously marketed Pillar Palatal Implants, in subjects treated for snoring and/or mild-to-moderate OSA.
|
From baseline to 30 days post-procedure
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change is Visual Analogue Scale (VAS) Score
大体时间:From baseline to 30 days post-procedure
|
The change in subjective snoring severity as measured by a 10 cm Visual Analogue Scale (VAS), scored 0-10, where 0 = no snoring and 10 = extremely annoying snoring (higher scores indicate worse outcome).
|
From baseline to 30 days post-procedure
|
|
Change in Snoring Outcomes Survey (SOS)
大体时间:From baseline to 30 days post-procedure
|
The change in subjective snoring as measured by the Snoring Outcomes Survey (SOS), an 8-item validated instrument assessing intensity, duration, frequency, and impact of snoring/sleep-disordered breathing symptoms.
|
From baseline to 30 days post-procedure
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in daytime Epworth Sleepiness Scale (ESS)
大体时间:From baseline to 30 days post-procedure
|
The change in daytime sleepiness as measured by the Epworth Sleepiness Scale (ESS), a validated 8-item questionnaire scored 0-24, where 0 = no daytime sleepiness and 24 = severe daytime sleepiness (higher scores indicate worse outcome).
|
From baseline to 30 days post-procedure
|
|
Change in Apnea-Hypopnea Index (bAHI3) via Home Sleep Apnea Test
大体时间:From baseline to 30 days post-procedure
|
AHI Score calculated using a 3% oxygen desaturation threshold (bAHI3), collected via the Belun Sleep System HSAT device.
Data will be anonymized; complete reports will be utilized as exploratory data.
|
From baseline to 30 days post-procedure
|
|
Change in Apnea-Hypopnea Index (bAHI4) via Home Sleep Apnea Test
大体时间:From baseline to 30 days post-procedure
|
AHI Score calculated using a 4% oxygen desaturation threshold (bAHI4), collected via the Belun Sleep System HSAT device.
|
From baseline to 30 days post-procedure
|
|
Change in Minimum Oxygen Saturation (SpO₂) via Home Sleep Apnea Test
大体时间:From baseline to 30 days post-procedure
|
Minimum SpO₂ recorded during the sleep study period, collected via the Belun Sleep System HSAT device.
|
From baseline to 30 days post-procedure
|
|
Change in Time with Oxygen Saturation ≤90% via Home Sleep Apnea Test
大体时间:From baseline to 30 days post-procedure
|
Total cumulative duration during which SpO₂ was recorded at or below 90%, collected via the Belun Sleep System HSAT device.
|
From baseline to 30 days post-procedure
|
|
Change in Sleep Efficiency via Home Sleep Apnea Test
大体时间:From baseline to 30 days post-procedure
|
Sleep efficiency calculated as the proportion of time in bed spent asleep, collected via the Belun Sleep System HSAT device.
|
From baseline to 30 days post-procedure
|
|
Change in Total Sleep Time (TST) via Home Sleep Apnea Test
大体时间:From baseline to 30 days post-procedure
|
Total duration of sleep recorded during the study period, collected via the Belun Sleep System HSAT device.
|
From baseline to 30 days post-procedure
|
|
Change in Mean Pulse Rate via Home Sleep Apnea Test
大体时间:From baseline to 30 days post-procedure
|
Mean pulse rate recorded during the sleep study period, collected via the Belun Sleep System HSAT device.
|
From baseline to 30 days post-procedure
|
|
Change in Arrhythmia Ratio via Home Sleep Apnea Test
大体时间:From baseline to 30 days post-procedure
|
Ratio of arrhythmic heartbeats to total heartbeats recorded during the sleep study period, collected via the Belun Sleep System HSAT device
|
From baseline to 30 days post-procedure
|
|
Change in Auditory Evaluation of Snoring
大体时间:From baseline to 30 days post-procedure
|
Outcome 6a: "Change in Objective Snoring Volume (decibels) via Audio Recording" - the change in mean snoring volume (dB) captured by at-home overnight audio recording. Outcome 6b: "Change in Objective Snoring Frequency (Hz) via Audio Recording" - the change in dominant snoring frequency captured by at-home overnight audio recording. |
From baseline to 30 days post-procedure
|
|
Proportion of Participants with Implant Migration or Trend Toward Extrusion as Assessed by Oropharyngeal Examination at 30 Days
大体时间:Date of procedure to 30 days post-implant
|
At each post-procedure visit (Day 7 and Day 30), the physician will conduct a standardized oropharyngeal examination to evaluate and document whether implant location has changed from the original placement position or is trending toward extrusion.
Findings will be recorded as a binary outcome (yes/no change in location) and summarized descriptively.
|
Date of procedure to 30 days post-implant
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- TESTING-055
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.